premix pentru broiler starter 1%
tekro ltd, cehia - complex - pulbere
premix pentru rațe starter 1%
tekro ltd, cehia - complex - pulbere
premix pentru purcei 0-2 luni
tekro ltd, cehia - complex - pulbere
radostin, (mc, p, ps, pgl, m, c, cs, cŢ), comprimate pentru câini
ooo nvŢ agrovetzaşcita, rusia - complex - comprimate
premix grower pentru porcine
nutrimin a/c, danemarca - complex - pulbere
premix breeder pentru porcine
nutrimin a/c, danemarca - complex - pulbere
hemoglovit sirop 17,5 mg + 3,5 mg/ml
vitapharm-com srl, im - de fier (iii) hydroxidum cu polymaltosi complex + viță de vie viniferae extract de semințe de - sirop - 17,5 mg + 3,5 mg/ml
imatinib actavis
actavis group ptc ehf - imatinib - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma - protein kinase inhibitors, antineoplastic agents - imatinib actavis is indicated for the treatment of: , paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment;, paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis;, adult patients with ph+ cml in blast crisis;, adult patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy;, adult patients with relapsed or refractory ph+ all as monotherapy;, adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements;, adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfr rearrangement;, the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. , efectul de imatinib pe rezultatul de transplantul de măduvă osoasă nu a fost determinată. imatinib actavis is indicated for: , in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic dfsp. experiența cu imatinib la pacienții cu mds/mpd asociate cu genei fcdp-re-aranjamente este foarte limitat. nu există studii controlate care să demonstreze un beneficiu clinic sau a crescut de supraviețuire pentru aceste boli.
macmiror complex 100 mg + 40000 ui/g cremă vaginală
polichem srl - nifuratelum + nystatinum - cremă vaginală - 100 mg + 40000 ui/g
macmiror complex 500 mg + 200000 ui capsule moi vaginale
polichem srl - nifuratelum + nystatinum - capsule moi vaginale - 500 mg + 200000 ui